Literature DB >> 3422801

Energy and protein metabolism in sarcoma patients.

J H Shaw1, D M Humberstone, R R Wolfe.   

Abstract

We have performed a series of isotopic infusions both in normal volunteers (N = 16) and in sarcoma patients (N = 7). Using the primed-constant infusion of stable or radioisotopes we have determined the rates of glucose turnover, glucose oxidation, glucose recycling, and net protein catabolism (NPC). In addition, we have measured VO2 and VCO2. The values for VCO2 and VO2 were higher in the patients than in the volunteers (mean VO2 values in volunteers and patients: 107 +/- 13 and 158 +/- 13 mumol/kg/min, respectively). The basal rate of glucose appearance in the sarcoma patients was twice the value seen in the volunteers (28.3 +/- 3.5 vs. 13.9 +/- 0.3 mumol/kg/min). Glucose infusion in the volunteers resulted in virtually total suppression of endogenous glucose production, while in the patients glucose infusion induced only a 30% suppression of endogenous glucose production (p less than 0.01). The rate of glucose clearance in the patients was approximately twice the value seen in the volunteers [5.4 +/- 1.0 vs. 2.7 +/- 0.1 mL/kg/min (p less than 0.01)]. The per cent of glucose uptake oxidized in the patients was significantly less than in the volunteers [22% vs. 36% (p less than 0.05)], and the per cent of glucose uptake that was recycled was significantly higher in the patients [55% vs. 10% (p less than 0.01)]. In addition, the basal rate of net protein loss was increased twofold in the patients [3.2 +/- 0.5 vs. 1.4 +/- 0.4 g (protein)/kg/d (p less than 0.01)], and in contrast to the situation in the volunteers there was no suppression in the rate of net protein loss when the patients were infused with glucose. The basal insulin concentration and the insulin response to glucose infusion in the patients were similar to that of the volunteers, but the plasma cortisol level was similar in volunteers and in the patients (p less than 0.05). We conclude from these studies the following: (1) Sarcoma patients have significantly elevated rates of glucose production and glucose clearance, but they have an impaired capacity to directly oxidize either endogenous or infused glucose, coupled with an increased rate of glucose recycling. (2) Sarcoma patients have an elevated metabolic rate and are catabolic. In addition, in contrast with normal volunteers, glucose infusion does not result in a suppression of protein loss.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3422801      PMCID: PMC1493415          DOI: 10.1097/00000658-198803000-00010

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  26 in total

Review 1.  Total parenteral nutrition in the cancer patient.

Authors:  M F Brennan
Journal:  N Engl J Med       Date:  1981-08-13       Impact factor: 91.245

2.  Evaluation of the role of the sympathetic nervous system in the response of substrate kinetics and oxidation to burn injury.

Authors:  R R Wolfe; M J Durkot
Journal:  Circ Shock       Date:  1982

3.  Isotopic determination of amino acid-urea interactions in exercise in humans.

Authors:  R R Wolfe; M H Wolfe; E R Nadel; J H Shaw
Journal:  J Appl Physiol Respir Environ Exerc Physiol       Date:  1984-01

4.  Albumin turnover in sarcoma-bearing rats in relation to cancer anorexia.

Authors:  H I Karlberg; K A Kern; J E Fischer
Journal:  Am J Surg       Date:  1983-01       Impact factor: 2.565

5.  Calculation of substrate oxidation rates in vivo from gaseous exchange.

Authors:  K N Frayn
Journal:  J Appl Physiol Respir Environ Exerc Physiol       Date:  1983-08

6.  Glucose metabolism in man: responses to intravenous glucose infusion.

Authors:  R R Wolfe; J R Allsop; J F Burke
Journal:  Metabolism       Date:  1979-03       Impact factor: 8.694

7.  Energy expenditure in malnourished gastrointestinal cancer patients.

Authors:  D T Dempsey; I D Feurer; L S Knox; L O Crosby; G P Buzby; J L Mullen
Journal:  Cancer       Date:  1984-03-15       Impact factor: 6.860

8.  Energy metabolism in nongrowing mice with sarcoma.

Authors:  L Lindmark; S Edström; L Ekman; I Karlberg; K Lundholm
Journal:  Cancer Res       Date:  1983-08       Impact factor: 12.701

9.  Measurement of urea kinetics in vivo by means of a constant tracer infusion of di-15N-urea.

Authors:  R R Wolfe
Journal:  Am J Physiol       Date:  1981-04

10.  Glucose metabolism and the percentage of glucose derived from alanine: response to exogenous glucose infusion in tumor-bearing and non-tumor-bearing rats.

Authors:  J M Arbeit; M E Burt; L V Rubinstein; C M Gorschboth; M F Brennan
Journal:  Cancer Res       Date:  1982-12       Impact factor: 12.701

View more
  6 in total

1.  Fructose-1,6-Bisphosphatase 2 Inhibits Sarcoma Progression by Restraining Mitochondrial Biogenesis.

Authors:  Peiwei Huangyang; Fuming Li; Pearl Lee; Itzhak Nissim; Aalim M Weljie; Anthony Mancuso; Bo Li; Brian Keith; Sam S Yoon; M Celeste Simon
Journal:  Cell Metab       Date:  2019-11-21       Impact factor: 27.287

2.  The effect of tumor bulk on the metabolic response to cancer.

Authors:  J B Koea; J H Shaw
Journal:  Ann Surg       Date:  1992-03       Impact factor: 12.969

Review 3.  Pathophysiology of cancer cachexia.

Authors:  U Keller
Journal:  Support Care Cancer       Date:  1993-11       Impact factor: 3.603

4.  Effect of growth hormone on tumor and host in an animal model.

Authors:  R F Wolf; B Ng; B Weksler; M Burt; M F Brennan
Journal:  Ann Surg Oncol       Date:  1994-07       Impact factor: 5.344

Review 5.  Perioperative care of the oncology patient.

Authors:  C J Kelly; J M Daly
Journal:  World J Surg       Date:  1993 Mar-Apr       Impact factor: 3.352

Review 6.  Lactate in Sarcoma Microenvironment: Much More than just a Waste Product.

Authors:  Maria Letizia Taddei; Laura Pietrovito; Angela Leo; Paola Chiarugi
Journal:  Cells       Date:  2020-02-24       Impact factor: 6.600

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.